Appointment of Radosław Krawczyk as Chief Financial Officer
Wrocław, June 29, 2021 – The Supervisory Board of Captor Therapeutics S.A. (WSE: CTX) has appointed Radosław Krawczyk to the Company's Management Board and entrusted him with the function of Chief Financial Officer. Radosław Krawczyk takes over from Aleksandra Skibińska who resigned from the position of Member of the Management Board and CFO after several years of leadership of the financial function, the conclusion of which was Captor’s successful initial public offering in April 2021. Being a part of an orderly transition, Radosław Krawczyk’s appointment is effective June 29, 2021.
“On behalf of the Board and management of Captor, I am very pleased to welcome Radosław to our team. He brings to Captor almost 20 years of experience in leadership roles with several public companies, where as CFO and a financial specialist he was deeply involved with all aspects of corporate finance, financial planning and accounting, as well as investor relations and stock exchange communications and compliance. We are confident that Radosław has the required financial leadership qualities to strongly contribute to the next phase of development of Captor and the execution of our international growth strategy. I would also like to thank Aleksandra for her excellent contribution to the growth of Captor from a start-up to a public company” said Dr Tom Shepherd, CEO and President of the Management Board, Captor Therapeutics.
Radosław Krawczyk has several years of professional experience, related to corporate finance and in particular: financial liquidity, financial risk, insurance and credit policy and M&A transactions. Since 2013 he was continuously associated with companies listed on the Warsaw Stock Exchange, where as part of his duties he was responsible for investor relations and contacts with analysts and investors. Until 2017, he was involved with PKP Cargo Group, serving as CFO and Board Member in the Group's subsidiaries in Poland and Germany. From 2017 to 2020 he was associated with OT Logistics Group; he was President of the Management Board of OT Logistics S.A. and was responsible for financial matters of the entire group and process of restructuring of the group. Radosław Krawczyk has also many years of experience in supervisory boards of various companies. He graduated from the Warsaw School of Economics, Faculty of Finance and Banking, as well as from MBA studies (Executive Master of Business Administration).
About Captor Therapeutics
Captor Therapeutics S.A. is a rapidly growing European biopharmaceutical company with principal operations in Wrocław, Poland. The Company operates in state-of the-art laboratories in the Wrocław Technology Park. Captor is also present in the Swiss Innovation Park, Allschwil, close to Basel, with its subsidiary Captor Therapeutics GmbH.
Captor Therapeutics focuses on the discovery and development of breakthrough drug candidates in diseases with high levels of unmet medical need using Targeted Protein Degradation (TPD). TPD is a revolutionary approach to finding new drugs that can address totally new molecular targets, currently not addressable using classical drugs, as well as improving the treatment options for diseases where existing drugs fail to prove optimal treatment. Captor is conducting, among others, five research and development projects aimed at developing drug candidates for the treatment of undertreated severe conditions, including malignancies and autoimmune diseases.
TPD technology is a transformational breakthrough because of its potential to target any protein, including proteins considered to be therapeutically un-targetable (undruggable Proteome). Captor Therapeutics is the European leader in TPD technology.
Captor Therapeutics currently has five R&D projects at the preclinical stage (four of which are at the lead optimisation phase).
The Company successfully closed the initial public offering of its shares in April 2021 and is listed on the Warsaw Stock Exchange.
More information on Captor Therapeutics is available at: http://www.captortherapeutics.com
For further information, please contact:
Michał Wierzchowski, cc group
telephone +48 531 613 067, email: email@example.com